Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

Truist raised the firm’s price target on Verona Pharma (VRNA) to $57 from $44 and keeps a Buy rating on the shares. The firm cites the ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...

Verona Pharma plc (VRNA), a biopharmaceutical company, Tuesday announced that the company expects preliminary unaudited fourth ...

Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...

Ensifentrine (Ohtuvayre) acts as bronchodilator and non-steroidal anti-inflammatory agent. It is formulated as suspension for inhalational route of administration. Ohtuvayre is indicated for the ...

A water main break in Verona prompted a 48-hour boil water advisory Thursday afternoon, according to town officials. When their taps ran dry, the water bottles came out for 15,000 affected Verona ...

Watch BBC's Steve Rosenberg challenge Putin on his 25 years in power in Russia. Video, 00:03:33Watch BBC's Steve Rosenberg challenge Putin on his 25 years in power in Russia ...

Barbara Obstoj-Cardwell is the Managing Editor of The Pharma Letter, which in 2010 acquired the archives of The Pharma Marketletter, a publication that Barbara owned since 1991 and prior to that ...